Administration of the human telomerase reverse transcriptase (hTERT) vaccine UV1 along with GM-CSF as an adjuvant activated anti-cancer T cell responses in 67% of patients with NSCLC (63). This evidence concerns the gene CSF2 and non-small cell lung carcinoma.